Bromocriptine

Base Information

• Chemical Name: Bromocriptine
• CAS No.: 25614-03-3
• Molecular Formula: C32H40 Br N5 O5
• Molecular Weight: 654.604
• European Community (EC) Number: 247-128-5
• UNII: 3A64E3G5ZO
• DSSTox Substance ID: DTXSID1022687
• Nikkaji Number: J16.988I
• Wikipedia: Bromocriptine
• Wikidata: Q413581
• NCI Thesaurus Code: C62010
• RXCUI: 1760
• Pharos Ligand ID: 33C4C16F7NQF
• Metabolomics Workbench ID: 43415
• ChEMBL ID: CHEMBL493
• Mol file: 25614-03-3.mol

Synonyms:2 Bromo alpha ergocryptine;2 Bromo alpha ergokryptine;2 Bromoergocryptine;2 Bromoergocryptine Mesylate;2 Bromoergocryptine Methanesulfonate;2 Bromoergokryptine;2-Bromo-alpha-ergocryptine;2-Bromo-alpha-ergokryptine;2-Bromoergocryptine;2-Bromoergocryptine Mesylate;2-Bromoergocryptine Methanesulfonate;2-Bromoergokryptine;Bromocriptin;Bromocriptine;Bromocriptine Mesylate;Bromocryptin;CB 154;CB-154;CB154;Mesylate, 2-Bromoergocryptine;Mesylate, Bromocriptine;Methanesulfonate, 2-Bromoergocryptine;Parlodel

Chemical Property of Bromocriptine

Chemical Property:

• Appearance/Colour: white crystalline powder
• Melting Point: 215-218° (dec)
• Refractive Index: 1.6400 (estimate)
• Boiling Point: 891.3 °C at 760 mmHg
• PKA: pKa 4.90±0.05(80% MCS t = RT) (Uncertain)
• Flash Point: 492.8 °C
• PSA: 118.21000
• Density: 1.52 g/cm³
• LogP: 3.39740
• Water Solubility.: 2.07mg/L(temperature not stated)
• XLogP3: 3.8
• Hydrogen Bond Donor Count: 3
• Hydrogen Bond Acceptor Count: 6
• Rotatable Bond Count: 5
• Exact Mass: 653.22128
• Heavy Atom Count: 43
• Complexity: 1230

Purity/Quality:

99%min ^*data from raw suppliers

Safty Information:

• Pictogram(s): Xn,Xi
• Hazard Codes: Xn,Xi

MSDS Files:

SDS file from LookChem

Useful:

• Drug Classes: Antiparkinson Agents
• Canonical SMILES: CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O
• Isomeric SMILES: CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O
• Recent ClinicalTrials: Bromocriptine for Patients With Schizophrenia and Impaired Glucose Tolerance
• Recent EU Clinical Trials: Dopamine action on metabolism depending on genetic heterogeneity – a randomized, placebo-controlled double blind study
• Recent NIPH Clinical Trials: The clinical intervention trial to post stroke depression and apathy
• Uses: Bromocriptine, a dopaminomimetic that is a dopamine D2 receptor agonist, possesses expressed antiparkinsonian activity. It is used for treating all phases of idiopathic and postencephalic Parkinsonism. Enzyme inhibitor (prolactin).
• Clinical Use: Bromocriptine is an ergot peptide derivative that is a partial agonist at D1-type and a full agonist at D2-type postsynaptic dopamine receptors, usually given in combination with levodopa therapy. It was the first direct dopamine receptor agonist used in treatment of Parkinson's disease after its development as an inhibitor of prolactin release (via activation of anterior pituitary D2 receptors). At low doses (typically 1–5 mg/day), bromocriptine is an effective prolactin inhibitor, and at higher doses (typically 10–20 mg/day), the antiparkinsonism and mood-elevating effects of bromocriptine become apparent.
• Drug interactions: Potentially hazardous interactions with other drugs Increased risk of toxicity with bromocriptine and isometheptene.

Technology Process of Bromocriptine

There total 11 articles about Bromocriptine which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 93.0%

α-ergocryptine (511-09-1) → Bromocriptine (25614-03-3)

Guidance literature:

With bromodimethylsulfoxonium bromide; In dimethyl sulfoxide; for 0.166667h; Ambient temperature;

Reference yield: 78.2%

α-ergocryptine (511-09-1,511-10-4,106188-95-8) → Bromocriptine (25614-03-3,65700-36-9,68944-89-8,82773-21-5,82796-58-5)

Guidance literature:

With piperidone-⁽²⁾-hydrotribromide; In 1,4-dioxane; for 0.0333333h; Ambient temperature;

Reference yield: 75.0%

→ Bromocriptine (25614-03-3)

Guidance literature:

upstream raw materials:

α-ergocryptine

trimethylsilyl bromide

α-ergocryptine phosphate

α-ergocryptine

Downstream raw materials:

Cycloset

Refernces

• 1、 -. "Process for the preparation of 2-bromo-8-ergolinyl compounds". . . Retrieved 2008/06/13.
• 2、 -. "Process for the preparation of 2-halogenated ergoline derivatives". . . Retrieved 2008/06/13.